Literature DB >> 20558579

Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma.

Daniel Martín-Pérez1, Esther Sánchez, Lorena Maestre, Javier Suela, Pierfrancesco Vargiu, Lorena Di Lisio, Nerea Martínez, Javier Alves, Miguel A Piris, Margarita Sánchez-Beato.   

Abstract

Polycomb proteins are known to be of great importance in human cancer pathogenesis. SUZ12 is a component of the Polycomb PRC2 complex that, along with EZH2, is involved in embryonic stem cell differentiation. EZH2 plays an essential role in many cancer types, but an equivalent involvement of SUZ12 has not been as thoroughly demonstrated. Here we show that SUZ12 is anomalously expressed in human primary tumors, especially in mantle cell lymphoma (MCL), pulmonary carcinomas and melanoma, and is associated with gene locus amplification in some cases. Using MCL as a model, functional and genomic studies demonstrate that SUZ12 loss compromises cell viability, increases apoptosis, and targets genes involved in central oncogenic pathways associated with MCL pathogenesis. Our results support the hypothesis that the abnormal expression of SUZ12 accounts for some of the unexplained features of MCL, such as abnormal DNA repair and increased resistance to apoptosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20558579      PMCID: PMC2913342          DOI: 10.2353/ajpath.2010.090769

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  58 in total

1.  Site-specific expression of polycomb-group genes encoding the HPC-HPH/PRC1 complex in clinically defined primary nodal and cutaneous large B-cell lymphomas.

Authors:  Frank M Raaphorst; Maarten Vermeer; Elly Fieret; Tjasso Blokzijl; Danny Dukers; Richard G A B Sewalt; Arie P Otte; Rein Willemze; Chris J L M Meijer
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

2.  Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.

Authors:  Jay D Raman; Nigel P Mongan; Satish K Tickoo; Stephen A Boorjian; Douglas S Scherr; Lorraine J Gudas
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma.

Authors:  José-Francisco Garcia; Giovanna Roncador; Juan-Fernando García; Ana-Isabel Sánz; Lorena Maestre; Elena Lucas; Santiago Montes-Moreno; Rebeca Fernandez Victoria; Jorge L Martinez-Torrecuadrara; Teresa Marafioti; David Y Mason; Miguel A Piris
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

5.  Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy.

Authors:  Antonis Kirmizis; Stephanie M Bartley; Peggy J Farnham
Journal:  Mol Cancer Ther       Date:  2003-01       Impact factor: 6.261

6.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

Authors:  Celina G Kleer; Qi Cao; Sooryanarayana Varambally; Ronglai Shen; Ichiro Ota; Scott A Tomlins; Debashis Ghosh; Richard G A B Sewalt; Arie P Otte; Daniel F Hayes; Michael S Sabel; Donna Livant; Stephen J Weiss; Mark A Rubin; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

7.  The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival.

Authors:  Nerea Martínez; Francisca I Camacho; Patrocinio Algara; Antonia Rodríguez; Ana Dopazo; Elena Ruíz-Ballesteros; Paloma Martín; Jose A Martínez-Climent; Javier García-Conde; Javier Menárguez; Fernando Solano; Manuela Mollejo; Miguel A Piris
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

8.  EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.

Authors:  Adrian P Bracken; Diego Pasini; Maria Capra; Elena Prosperini; Elena Colli; Kristian Helin
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

9.  PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.

Authors:  Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

10.  Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines.

Authors:  Danny F Dukers; Joost C van Galen; Cindy Giroth; Patty Jansen; Richard G A B Sewalt; Arie P Otte; Hanneke C Kluin-Nelemans; Chris J L M Meijer; Frank M Raaphorst
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

View more
  20 in total

1.  Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12.

Authors:  Zongtao Xie; Liming Cai; Runsheng Li; Jinyu Zheng; Hongyan Wu; Xiaoqi Yang; Hu Li; Zhiqiang Wang
Journal:  Tumour Biol       Date:  2015-04-02

Review 2.  Polycomb genes, miRNA, and their deregulation in B-cell malignancies.

Authors:  Gang Greg Wang; Kyle D Konze; Jianguo Tao
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

3.  SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis.

Authors:  Chunhua Liu; Xuefei Shi; Li Wang; Ying Wu; Feiyan Jin; Cuiqing Bai; Yong Song
Journal:  Tumour Biol       Date:  2014-03-15

4.  Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.

Authors:  Warren Fiskus; Rekha Rao; Ramesh Balusu; Siddhartha Ganguly; Jianguo Tao; Eduardo Sotomayor; Uma Mudunuru; Jacqueline E Smith; Stacey L Hembruff; Peter Atadja; Victor E Marquez; Kapil Bhalla
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

5.  SUZ12 promotes gastric cancer cell proliferation and metastasis by regulating KLF2 and E-cadherin.

Authors:  Rui Xia; Fei-yan Jin; Kai Lu; Li Wan; Min Xie; Tong-peng Xu; Wei De; Zhao-xia Wang
Journal:  Tumour Biol       Date:  2015-02-12

6.  Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.

Authors:  Yan-Long Liu; Xu Gao; Yang Jiang; Gan Zhang; Zi-Cheng Sun; Bin-Bin Cui; Yan-Mei Yang
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-19       Impact factor: 4.553

7.  Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

Authors:  X Zhao; T Lwin; X Zhang; A Huang; J Wang; V E Marquez; S Chen-Kiang; W S Dalton; E Sotomayor; J Tao
Journal:  Leukemia       Date:  2013-03-29       Impact factor: 11.528

8.  SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.

Authors:  Hua Li; Qi Cai; Hong Wu; Vinod Vathipadiekal; Zachary C Dobbin; Tianyu Li; Xiang Hua; Charles N Landen; Michael J Birrer; Margarita Sánchez-Beato; Rugang Zhang
Journal:  Mol Cancer Res       Date:  2012-09-10       Impact factor: 5.852

Review 9.  Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Nag; Jianwei Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2015-07-30       Impact factor: 12.944

10.  MiR-449a suppresses cell invasion by inhibiting MAP2K1 in non-small cell lung cancer.

Authors:  Jiacong You; Yalong Zhang; Yang Li; Nianzhen Fang; Bin Liu; Lingling Zu; Qinghua Zhou
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.